Efficacy of gamma globulin and methylprednisolone in treatment ofmyasthenia gravis and their effects on lymphocyte subsets and Treg/Th17
Objective To explore the efficacy of gamma globulin and methylprednisolone in the treatment of myasthenia gravis,as well as their effects on lymphocyte subsets and regulatory T cells(Treg)/helper T cell 17(Th17).Methods Aprospective study was conducted on 80 patients with myasthenia gravis admitted to our hospital from July 2020 to October 2022.The patients were randomly divided into a study group of 40 cases and a control group of 40 cases.The control group received methylprednisolone treatment,while the study group received gamma globulin treatment on the basis of the control group.Both groups were treated for 6 months,and the efficacy and lymphocyte subgroup indicators(CD3+,CD4+,CD8+,CD4+/CD8+,CD4+/CD25+)were compared between the two groups Differences in Treg(percentage of Treg,CD4+CD25+FOX3+),Th17 cells,and adverse reactions.Results The rank sum test results of the hierarchical data showed that there was a statistically significant difference in the efficacy between the two groups after 3 months of treatment and 6 months of treatment(Z=8.344,4.944,P＜0.05),and the total efficacy rate of the study group after 3 months of treatment and 6 months of treatment was higher than that of the control group(P＜0.05).After 6 months of treat-ment,the levels of CD3+,CD4+,CD4+/CD8+in both groups of patients increased compared to before treatment(P＜0.05),while CD8+and CD4+/CD25+decreased(P＜0.05).Moreover,the increase and decrease in lymphocyte subpopulation related indicators in the study group after 6 months of treatment were better than those in the control group(P＜0.05).The results of repeated measurement analysis of variance showed that after 3 months and 6 months of treat-ment,the frequency of Th17 cells and Treg in both groups significantly decreased compared to before treatment,while the percentage of CD4+CD25+FOX3+decreased(P＜0.05).Moreover,the increase and decrease in the above indicators in the study group after 3 months and 6 months of treatment were better than those in the control group(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions and the overall incidence of adverse reactions between the two groups of patients(P＞0.05).Conclusion The combination of gamma globulin and methylprednisolone has a good therapeutic effect on myasthenia gravis,which can be achieved by regulating Treg/Th17 cell values,improving the body's immune function,and ultimately exerting therapeutic effects.
Myasthenia gravisGamma globulinMethylprednisoloneEfficacyLymphocyte subpopulationsRegulatory T cellsHelper T cells 17
NETL
NSTL
万方数据
